Metastatic Colorectal Cancer (mCRC) Patients Treated with Later Lines of Treatment (LOT): A Retrospective Analysis By Race and Ethnicity in the United States (US) Community Oncology Setting
Author(s)
Barzi A1, Appukkuttan S2, Hocum B2, Katta A3, Babajanyan S2, Cosgrove D4, Sruti I5, Shi J5, Dai W5, Patton G6, Bekaii-Saab T7
1City of Hope Comprehensive Cancer Centre, Duarte, CA, USA, 2Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ, USA, 3Bayer Healthcare Pharmaceuticals, Inc., Jersey City, NJ, USA, 4Compass Oncology, Woodland, TX, USA, 5Ontada, Irving, TX, USA, 6Ontada, Boston, MA, USA, 7Mayo Clinic - Phoenix, Phoenix, AZ, USA
Presentation Documents
OBJECTIVES:
Regorafenib (REGO) and trifluridine/tipiracil (FTD/TPI) extend overall survival in metastatic colorectal cancer (mCRC) patients previously treated with fluoropyrimidine-based chemotherapies. mCRC outcomes vary significantly by race and ethnicity. In this real-world study, we evaluated patients who initiated REGO and/or FTD/TPI in any LOT from a community oncology setting, stratified by racial and ethnic groups.METHODS:
A retrospective analysis utilizing electronic medical record data from The US Oncology Network examined adult patients with mCRC who initiated REGO or FTD/TPI between 09/01/2015 and 03/31/2022 (index date), with follow-up until 09/30/2022. Baseline demographic, clinical characteristics, and treatment characteristics were reported for white and minority (Black, Hispanic, Latino or Asian) patients.RESULTS:
Among 2684 mCRC patients initiating REGO or FTD/TPI in any LOT, 1599 were white and 556 were minorities. Mean ages for white and minority patients were 63 (SD 11.6) and 62 (SD 11.5) years, respectively, and median follow-up periods were 6.5 and 6.2 months. The median (interquartile range) time from mCRC diagnosis to index date was 20.9 (12.6, 34.1) months for white patients and 19.8 (11.6, 29.7) months for minority patients. White patients most frequently initiated REGO in 4L (15.7%) and FTD/TPI in 4L (17.1%). Minority patients most frequently initiated REGO in 3L (16.2%) and FTD/TPI in 4L (18.5%). The most common prior chemotherapy regimens were FOLFIRI-based (white 60%, minority 66%) and FOLFOX-based regimens (white 50%, minority 54%). The majority of all patients had previous exposure to anti-VEGF therapy (white 80%, minority 81%), of which bevacizumab was the most common agent (white 79%, minority 80%).CONCLUSIONS:
Within US Oncology database, baseline demographic and clinical characteristics were similar for white and minority patients. There appears to be a trend of earlier initiation of REGO among minority patients. Further research on clinical outcomes in white and minority populations is necessary.Conference/Value in Health Info
Value in Health, Volume 27, Issue 6, S1 (June 2024)
Code
HSD106
Topic
Epidemiology & Public Health, Health Policy & Regulatory
Topic Subcategory
Health Disparities & Equity, Safety & Pharmacoepidemiology
Disease
Drugs, Gastrointestinal Disorders, Oncology